1. Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response
- Author
-
Xiang-Ping Li, Ji-Ye Yin, Yi Zheng, Yu Zhang, Juan Chen, Wei Zhang, Hong-Hao Zhou, Chen-Yue Qian, Chao Fang, Zhao-Qian Liu, Ying Wang, Ling Xiao, Hui He, Zhan Wang, and Sai-Ying Wang
- Subjects
Male ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Genotype ,medicine.medical_treatment ,Platinum Compounds ,Polymorphism, Single Nucleotide ,CCN Intercellular Signaling Proteins ,Signaling Pathway Protein ,Asian People ,Carcinoma, Non-Small-Cell Lung ,Proto-Oncogene Proteins ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,medicine ,Humans ,Genetic Predisposition to Disease ,Lung cancer ,Chemotherapy ,Lung ,business.industry ,Wnt signaling pathway ,Middle Aged ,respiratory system ,medicine.disease ,Lung cancer susceptibility ,respiratory tract diseases ,Treatment Outcome ,medicine.anatomical_structure ,Case-Control Studies ,Female ,business ,Chemotherapy response - Abstract
Background Platinum-based chemotherapy is the main treatment method for lung cancer patients. The genetic polymorphisms of Wnt-inducible signaling pathway protein 1 ( WISP1 ) were reported to be associated with the development of diverse lung diseases. In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response in Chinese lung cancer patients. Materials and Methods A total of 556 lung cancer patients and 254 healthy controls were enrolled onto this study. The 28 polymorphisms of the WISP1 gene were genotyped by the Sequenom MassARRAY system. Results We found that WISP1 rs16893344, rs2977530, rs2977537, and rs62514004 ( P = .009, .033, .049, and .036, respectively) polymorphisms were related to susceptibility of lung cancer; and WISP1 rs11778573 ( P = .023, nonsmokers), rs16893344 ( P = .013, ≥ 50 years old), rs2977536 ( P = .039, ≥ 50 years old; P = .044, nonsmokers; P = .047, non–small-cell lung cancer, respectively), rs2977549 ( P = .013, smokers), and rs62514004 ( P = .033, ≥ 50 years old) polymorphisms were significantly associated with platinum-based chemotherapy response in lung cancer patients. Conclusion Genotypes of WISP1 may be novel and useful biomarkers for diagnosis of lung cancer and evaluation of platinum-based chemotherapy response in lung cancer patients.
- Published
- 2015
- Full Text
- View/download PDF